Abstract
ObjectiveCervical cancer is the fourth most frequent neoplasm among women in terms of incidence and mortality. Health-related quality of life (HRQL) is an important outcome in oncology. The QLQ-CX24 instrument was developed to measure HRQL in patients with cervical cancer, and its Mexican-Spanish version had not been validated.MethodsBetween March 2018 and May 2019, Mexican women older than 18, with any-stage cervical cancer were invited to participate in the study. Patients answered the QLQ-C30 and QLQ-CX24 questionnaires. Current tests for psychometric and clinical validation were performed.ResultsThree hundred and thirty patients with cervical cancer were included in this study. All women invited to participate accepted and were included. The QLQ-CX24 internal consistency test demonstrated adequate convergent (Spearman correlation coefficient 0.001–0.847) and divergent validity (Spearman correlation coefficient <0.0001–0.45). Cronbach’s alpha coefficients of the three multi-item scales were >0.7 (minimum 0.76, maximum 0.89). Four scales of the QLQ-CX24 distinguished patients in different clinical stages. The evaluation of responsiveness demonstrated that the peripheral neuropathy scale was sensitive to change over time during chemo-radiation therapy. Six scales of the QLQ-CX24 instrument were associated with survival.ConclusionThe Mexican-Spanish version of the QLQ-CX24 questionnaire is reliable and valid for the assessment of HRQL in patients with cervical cancer.
Subject
Obstetrics and Gynaecology,Oncology
Reference25 articles.
1. Ferlay J , Ervik M , Lam F . Global cancer observatory, 2018. Cancer Today Lyon, France: International Agency for Research on Cancer. Available: https://gco.iarc.fr/today [Accessed 20 Apr 2021].
2. Epidemiological profile, gastrointestinal toxicity, and treatment of pelvic cancers in patients managed with radiotherapy to the abdominal pelvic area;Cetina-Pérez;Rev Invest Clin,2018
3. Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix
4. Radiation enteropathy—pathogenesis, treatment and prevention
5. Patient-reported outcomes in cancer drug development and US regulatory review: perspectives from industry, the Food and Drug Administration, and the patient;Basch;JAMA Oncol,2015
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献